News

In a meta-analysis spanning 10 studies of 1300 patients with Alzheimer disease, global cognition, as measured by the Mini-Mental State Examination or ADAS-Cog, was improved using noradrenergic drugs.

The presence of concurrent psychogenic nonepileptic seizures increased the odds of hospitalization for first suicide by 152% compared with epilepsy alone.

In comparison with controls, there were no significant differences in MRI volumes, amyloid-ß or tau accumulation, nor in most longitudinal measures among those with traumatic brain injury and/or PTSD.

In comparison to those with consistently low depressive symptoms, those with consistently high, fluctuating, and increasing depressive trajectories had 18% to 31% higher hazard of developing incident stroke.

The director of the Montefiore Headache Center provided an overview of the recent advances in migraine medications and how it has translated to improved care. [WATCH TIME: 2 minutes]

The chair of Cleveland Clinic’s Department of Physical Medicine provided commentary on the goals for the newly approved EksoNR robotic exoskeleton in rehabilitative efforts for patients with multiple sclerosis.

Over a 2-year period, apitegromab-treated patients demonstrated sizable and sustained improvements in Hammersmith Functional Motor Scale-Expanded and substantial increases in Revised Upper Limb Module scores.

The neurologist and movement disorders fellow at University Hospitals Cleveland Medical Center shared his experiences engaging with a diverse community of clinicians at the ATMRD Congress and in clinical practice. [WATCH TIME: 2 minutes]

The risk of developing Alzheimer disease and related dementias decreased gradually with increasing scores in a dose-response manner on a model geared toward identifying healthy lifestyle factors.

Get caught up on some of the latest news in epilepsy and seizure disorders, with data updates and expert insights, all in one place from the NeurologyLive® team.

Taldefgrobep alfa, a muscle-targeted experimental treatment potentially used in combination with other SMA therapies, will be evaluated in a cohort of 180 patients with SMA, regardless of ambulatory status or disease classification.

On a per-capita basis, a hospital serving a predominately Black, racially segregated community was 26% less likely to adopt stroke certification of any level than a hospital in a predominately non-Black, racially segregated community.

The director of the Montefiore Headache Center provided commentary on how analyses presented at AHS 2022 further support the benefits intranasal zavagepant bring to the migraine treatment landscape. [WATCH TIME: 5 minutes]

Here's what is coming soon to NeurologyLive®.

Of the patients with drug-resistant epilepsy in the cohort, 54% had status epilepticus during their acute admission, and 2 of 3 patients with NORSE ended up developing drug-resistant epilepsy at 12 months.

The director of the Montefiore Headache Center provided insight on an open-label study presented at AHS 2022 that highlighted rimegepant’s (Nurtec ODT; Biohaven) impact both as a preventative and acute medication. [WATCH TIME: 5 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is stroke and cerebrovascular disease.

After 3 instances of clinically significant, transient hypotension—which resolved after treatment halt—recruitment for the trial of the investigational recombinant KLK1 tissue protein has been paused.

The net clinical benefit with ticagrelor and aspirin over clopidogrel and aspirin treatment may be predominant in the first week, with additional small benefit in the second and third weeks for those with minor ischemic stroke or transient ischemic attack.

Neurology News Network for the week ending July 9, 2022. [WATCH TIME: 4 minutes]

Those with the common thyroid disorder displayed a more than 80% increased risk of dementia, with a more than 3-fold increase in the risk among those requiring hormone replacement therapy.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 8, 2022.

In addition to meeting primary end point of change in North Star Ambulatory Assessment, treatment with SRP-9001 resulted in statistically significant improvements in timed function tests.

Get caught up on some of the latest news in movement disorders, with data updates and expert insights, all in one place from the NeurologyLive® team.

Ruth Benca, MD, PhD, a professor and the chair of Psychiatry & Human Behavior at Wake Forest School of Medicine, provided insight on the age- and sex-related differences in sleep disorders, and the needed research on the effects of therapeutics in older populations.

The pediatric neurologist and headache specialist at the University of Calgary and Alberta Children’s Hospital spoke about the need for improved funding and research efforts for the migraine population. [WATCH TIME: 5 minutes]

Expert clinicians offer their insight on the sleep disorder landscape, the state of mental health in pediatric migraine, an inaugural movement disorders congress, a novel stroke rehabilitation tool, and psychedelics in cluster headache.

The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology provided insight on a unique way the institution cares for patients who present with an inflammatory or autoimmune entity. [WATCH TIME: 5 minutes]